All News

EULAR flags

Digital Platforms and AI

2026 EULAR Press Release

EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.

Read Article
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Catching your breath session at #EULAR2026 RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr) Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks) @RheumNow https://t.co/V1JXM3i9wP

Links:

Jiha Lee JihaRheum ( View Tweet)
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

EULAR 2026: Industry Press Releases Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will https://t.co/2czkdWKtEO
Dr. John Cush RheumNow ( View Tweet)
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026 Presence on leucocytes- change from pro inflammatory to anti inflammatory casade Also in fibroblasts in rheumatoid arthritis. Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv

Links:

Bella Mehta bella_mehta ( View Tweet)
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Prof. Wittmann discusses the current tx for CLE using a stepwise approach. Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ

Links:

sheila RHEUMarampa ( View Tweet)
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow Summary below. https://t.co/QC0Li38eh6

Links:

Bella Mehta bella_mehta ( View Tweet)
After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2026 POS0729 Longer-term data of autologous CD19 CAR-T appear favourable in #SLE. 4-year data of the initial 8 patients treated at Erlangen remained in GC- and IS-free remission. Infection profile declined over time apart from some blips during COVID pandemic @RheumNow https://t.co/QZMxA2CK33

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC

Links:

Janet Pope Janetbirdope ( View Tweet)
Leflunomide is not associated w/ incident or progressive ILD Longitudinal CT Study 184 RA pts LEF exposure inversely asso w/ new lung involvement #POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Brand new #MOA in #Rx of #skin #lupus! #Litifilimab - acts on #dendritic cells ⬇️decreases #chemokines & #cytokines +RCT in #cutaneous features of lupus N=93 2:1 randomized #liti v #pbo Rapid onset <4wks HIgh #CLASI response #EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU

Links:

Janet Pope Janetbirdope ( View Tweet)
SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×